Previous 10 | Next 10 |
Short-sellers gained a lot of attention in recent days as they rushed to cover positions in rapidly rising stocks such as GameStop (NYSE: GME) . In this case, they lost their bets on the stock's decline -- and their money. But in some cases, the shorted stock does fall. And shor...
Shares of Vaxart (NASDAQ: VXRT) surged 109.8% in January, according to data provided by S&P Global Market Intelligence , adding onto the colossal 1,530% gain the stock made across all of 2020. Essentially a penny stock at the start of last year, Vaxart vaulted to the...
A few days ago, Vaxart (NASDAQ: VXRT) was arguably the best-performing coronavirus vaccine stock of all time. If you had invested $5,000 in the stock last year, that principal would have grown into a stunning $205,000 by Feb. 2. But not even 24 hours later, Vaxart ...
On Feb 3, Vaxart announced "Positive" Preliminary Data from its Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate. Vaxart reported that the study reached primary and secondary endpoints of safety and immunogenicity. VXA-CoV2-1 induced potent CD8+ T-cell resp...
Vaxart (NASDAQ: VXRT) has seemingly fallen further behind in the coronavirus vaccine race. On Monday, the company unveiled preliminary data from a phase 1 study of its vaccine candidate, VXA-CoV2-1, that showed a potentially significant weakness. The company reported that its or...
Vaxart (NASDAQ: VXRT) ranked as one of the hottest coronavirus stocks of 2020. Its share skyrocketed over 1,500% last year as investors became increasingly excited about the biotech's oral COVID-19 vaccine candidate, VXA-CoV2-1. As of the market close on Tuesday, Vaxart's share pric...
Shares of Vaxart (NASDAQ: VXRT) plunged 58% on Wednesday after the biotech released data from a phase 1 study of its oral COVID-19 vaccine candidate, VXA-CoV2-1. Preliminary results from Vaxart's clinical trial showed VXA-CoV2-1 to be generally well-tolerated, with no severe...
Gainers: Tyme Technologies (TYME) +93%.Sino-Global Shipping America (SINO) +81%.Lizhi (LIZI) +70%.Cassava Sciences (SAVA) +48%.GW Pharmaceuticals (GWPH) +46%.CPS Technologies (CPSH) +41%.10X Capital Venture Acquisition (VCVC) +38%.Naked Brand (NAKD) +37%.SuperCom (SPCB) +34%.Am...
Vaxart (NASDAQ: VXRT) , an American biotechnology company, announced that its preliminary oral COVID-19 vaccine had demonstrated positive results in early-stage clinical trials featuring 35 healthy adults. Nevertheless, the company’s stock fell 60% during intraday trading. ...
Gainers: Tyme Technologies (TYME) +110%, GW Pharmaceuticals (GWPH) +47%, Zynerba Pharmaceuticals (ZYNE) +39%, SELLAS Life Sciences (SLS) +38%, InMed Pharmaceuticals (INM) +15%.Losers: Vaxart (VXRT) -51%, Moleculin Biotech (MBRX) -26%...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...